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 24 
Abstract 25 
Normal placental function is essential for optimal fetal growth. Transport of glucose from 26 
mother to fetus is critical for fetal nutrient demands and can be stored in the placenta as 27 
glycogen. However, the function of this glycogen deposition remains a matter of debate: It 28 
could be a source of fuel for the placenta itself or a storage reservoir for later use by the fetus 29 
in times of need. While the significance of placental glycogen remains elusive, mounting 30 
evidence indicates that altered glycogen metabolism and/or deposition accompanies many 31 
pregnancy complications that adversely affect fetal development. This review will summarise 32 
histological, biochemical and molecular evidence that glycogen accumulates in a) placentas 33 
from a variety of experimental rodent models of perturbed pregnancy, including maternal 34 
alcohol exposure, glucocorticoid exposure, dietary deficiencies and hypoxia and b) placentas 35 
from human pregnancies with complications including preeclampsia, gestational diabetes 36 
mellitus and intrauterine growth restriction (IUGR). These pregnancies typically result in 37 
altered fetal growth, developmental abnormalities and/or disease outcomes in offspring. 38 
Collectively, this evidence suggests that changes in placental glycogen deposition is a 39 
common feature of pregnancy complications, particularly those associated with altered fetal 40 
growth. 41 
 42 
Keywords: placental glycogen, diabetes, IUGR, preeclampsia, rodent models, glycogen 43 
trophoblast cells 44 
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 46 
Introduction 47 
Delivery of a healthy baby of optimal weight and size is largely dependent upon a well-48 
functioning placenta. The placenta functions as the interface between the maternal blood 49 
supply and the developing fetus and is responsible for the oxygen and nutrient delivery 50 
required for normal fetal growth. Many perinatal complications including miscarriage, 51 
abnormal fetal growth and even some fetal defects can be attributed to poor placental 52 
function [1, 2]. In addition, major obstetric complications such as early onset preeclampsia 53 
[3] also directly involve placental dysfunction. However, the impact of poor placental 54 
function does not cease upon delivery. There has been renewed interest in placental biology 55 
due to our understanding that many diseases of adulthood, including cardiovascular disease, 56 
diabetes and even mental disorders, have their origins in utero [4]. 57 
One aspect of placental morphology that appears to be indicative of alterations to normal fetal 58 
growth is excessive glycogen deposition. This review will begin by briefly summarising the 59 
importance of the placenta for short and long-term health outcomes in offspring and the 60 
pregnancy complications that can interfere with this role. It will then present current 61 
knowledge on the normal process of glycogen storage and handling in the placenta during 62 
pregnancy, in both human and preclinical rodent models, and how this is thought to link to 63 
fetal nutrient demands and growth. Finally, preclinical and clinical evidence for altered 64 
glycogen deposition during various pregnancy complications will be summarised and 65 
discussed. 66 
 67 
The impact of pregnancy complications on placental function, fetal growth and long-68 
term offspring health 69 
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The placenta regulates the extent to which a healthy birth weight is achieved. Glucose and 70 
amino acids are the primary energy substrates required by the developing fetus and placenta 71 
and reductions in their availability result in reduced fetal growth and low birth weight [5]. 72 
The health and nutritional status of the mother can directly influence the availability of these 73 
substrates and thus impact on placental development [6]. This impairment often manifests as 74 
poor trophoblast invasion and spiral artery remodelling, or reduced vascularization and 75 
expansion of the villous tree. This can cause poor placental perfusion or a reduced surface 76 
area for substrate exchange respectively [7]. These disruptions can reduce the amount of 77 
glucose or amino acids transferred to the fetus and cause growth restriction. 78 
In the human, many obstetric complications are directly related to placental abnormalities. 79 
The best characterized is preeclampsia (PE) which affects ~5-10% of pregnancies worldwide 80 
and is a major cause of preterm delivery and perinatal morbidity [8]. PE, particularly early-81 
onset PE, significantly increases the risk for fetal growth restriction and this is thought to be 82 
due to complications in spiral artery remodelling leading to placental insufficiency [9]. Of 83 
great interest in current society is the effect of excess maternal glucose and nutrients which 84 
occur in maternal diabetes or obesity. With more than 40% of pregnant women being 85 
overweight or obese [10], there are increasing numbers of women with type 2 diabetes 86 
entering pregnancy or subsequently developing gestational diabetes. This often contributes to 87 
the delivery of large for gestational age (LGA) babies [11]. In diabetic pregnancies, the 88 
placenta undergoes structural and functional changes dependent on the modality and quality 89 
of glycemic control [12]. These include alterations to the insulin/IGF system [13] as well as 90 
cytokines similar to those found in adipose tissue that regulate insulin action [12]. 91 
Additionally, factors regulating glucose and lipid metabolism such as FGF21 and GLUT3 are 92 
dysregulated in diabetic placentas [14].  93 
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Rodent models also provide evidence that pregnancy complications can affect placental 94 
function and fetal growth. Maternal hypoxia, which in humans may be caused by smoking, 95 
asthma or sleep apnea, has been shown to alter placental development and expression of 96 
glucose transporters in mouse models [15, 16]. This limits both oxygen and nutrients to the 97 
fetus, resulting in intrauterine growth restriction (IUGR). 98 
Early studies associating fetal growth and adult health outcomes found the most severely 99 
affected individuals were those with a low birth weight to placental weight ratio. These 100 
individuals had a blood pressure ~25 mmHg higher than the groups with the healthiest birth 101 
and placental weights [1]. Other studies suggested a U-shaped relationship between the birth 102 
weight to placental weight ratio, as males born with placentas large or small for their body 103 
weight have an increased incidence of coronary heart disease as adults [17]. This dichotomy 104 
may be due to limited nutrient transfer in a small placenta versus diversion of maternal 105 
nutrients by a large placenta to meet its own needs. Collectively, these studies indicate the 106 
importance of a normally functioning placenta capable of balancing maternal-fetal nutrient 107 
exchange to fetal outcomes and long-term offspring health. 108 
 109 
Glycogen deposition in the human placenta during pregnancy 110 
Glycogen, a form of stored glucose, is readily deposited in tissues where glucose needs to be 111 
easily mobilised such as the liver and skeletal muscle. Whilst it is known the placenta can 112 
also store glycogen, there are relatively few studies examining glycogen in the human 113 
placenta. 114 
In normal pregnancies, glycogen accumulation begins as early as the first trimester [18], but 115 
declines towards term [19]. A region in the human placenta known as the basal plate (bp) 116 
contains multilayered columns of cytotrophoblast cells, located at the ends of villi, and 117 
extravillous cytotrophoblast cells (EVT). EVT proximal to the villi contain low amounts of 118 
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glycogen while the distal EVT are vacuolated and glycogen rich [20]. Strong staining for 119 
glycogen has also been reported in cytotrophoblast cells of chorionic villi in the placenta in 120 
early pregnancy, gradually decreasing in intensity as the pregnancy progresses [21]. In late 121 
first trimester placenta, some fibroblast cells also contain glycogen aggregates [22], but it is 122 
not clear if this continues throughout gestation or if it is affected by pregnancy complications. 123 
Transport of glucose from mother to fetus is particularly critical to meet fetal nutrient 124 
demands and is controlled by a number of specific placental glucose transporters (see [23] for 125 
review). In the placenta, glucose can be converted into glycogen for storage either via the 126 
classical pathway (glycogen synthase) or through using glycogenin as a primer [18]. In 127 
healthy human placenta, it appears that glycogen synthesis via the classical pathway and 128 
degradation occurs in syncytiotrophoblasts, cytotrophoblasts and the decidua in the first 129 
trimester of pregnancy but is absent at term [24]. In term placenta, glycogen synthesis via the 130 
glycogenin pathway is stronger in endothelial cells, syncytiotrophoblasts, extravillous 131 
trophoblasts and basal decidual cells than in first trimester [18]. In the decidua, glycoprotein 132 
production helps to provide nutrients early in gestation and glycogen synthesis and 133 
breakdown may contribute by providing substrates to this process. The metabolically active 134 
Hofbauer cells express low levels of glycogen synthase but their expression of glycogen 135 
phosphorylase is more pronounced both early in gestation as well as at term [22]. However, 136 
glycogen aggregation does not occur in Hofbauer cells even though the expression of GLUT3 137 
suggests that glucose is transported into these cells [22]. This suggests that Hofbauer cells, 138 
which are placental macrophages, are not a site for glycogen storage in healthy human 139 
placentas at term.  140 
 141 
Glycogen deposition in the rodent placenta during pregnancy 142 
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In the mouse, more is known about glycogen levels in the placenta during pregnancy and in 143 
particular, the development of specialised glycogen trophoblast cells (GlyT) cells. GlyT are 144 
born in the centre of the ectoplacental cone (EPC), an earlier structure that gives rise to the 145 
junctional zone (jz) around E7.5. The jz is centrally located within the mouse placenta and is 146 
thought to provide physical support to the underlying vascular exchange structures [25], as 147 
well as serving an important endocrine role [26, 27]. GlyT cells share a common lineage with 148 
the endovascular invading, spiral artery remodelling trophoblast giant cells [28]. From 149 
~E10.5-E12.5, GlyT begin to accumulate glycogen and can be found as tightly packed 150 
clusters embedded within spongiotrophoblast cells (SpT) (Fig. 1). After E12.5, GlyT begin to 151 
break out of the jz and invade interstitially into the maternal decidua [29] and congregate 152 
around spiral arteries and former sites of uterine natural killer cells (uNK) [30]. Interstitial 153 
invasion of GlyT continues until E18.5, at which time a 50% decline in numbers is observed 154 
[31]. Glycogen stores have also been reported to decline in the jz of the rat placenta between 155 
E16 and E19 by more than 3-fold [32]. Interestingly, GlyT then enter a lytic/apoptotic phase 156 
near the end of gestation (~E18.5), forming large glycogen filled lacunae in the vicinity of 157 
vascular sinuses, suggesting they provide a source of energy at the end of term or perhaps 158 
influence parturition [28].  159 
Superficially, the human and mouse placenta are quite different, although considerable 160 
regional and cellular analogies exist [20]. As discussed above, glycogen deposition occurs in 161 
more placental cell types within the human placenta than in rodents, which have glycogen 162 
specifically in GlyT cells. The jz of the rodent placenta is thought to be analogous to the 163 
human bp. In addition, the interstitial invasion by GlyT cells into the maternal decidua late in 164 
gestation is comparable to interstitial EVTs that invade deep into the decidua of the human 165 
placenta. The low glycogen EVTs proximal to the villi are reminiscent of murine SpT cells, 166 
while the high glycogen distal EVTs are similar to murine GlyT cells [20]. Also, many of the 167 
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genes known to regulate placental formation in the mouse are expressed in analogous cell 168 
types in human placenta [25] and there are many shared genetic pathways utilized in 169 
placentation by both species [20]. Importantly, the compartmentalization of glycogen storage 170 
to a specialized glycogen trophoblast subtype within the mouse placenta offers a unique 171 
opportunity to manipulate putative genes involved in placental glycogen handling and 172 
interrogate the effects of such manipulations on fetal growth and development. 173 
 174 
What is the putative function of glycogen in the placenta? 175 
As discussed above, glucose can be stored in the placenta in the form of glycogen in both 176 
human and rodent pregnancies. However, the function of this glycogen deposition remains a 177 
matter of debate and, certainly, its role in complicated pregnancies that result in changes to 178 
fetal growth are unknown. At least in healthy pregnancies, stored glycogen is hypothesized to 179 
be important for times when feto-placental demand for glucose exceeds supply from the 180 
maternal circulation, such as late in gestation [31]. Constitutive placental glycogen storage 181 
appears to vary during pregnancy in a sex-dependent manner, at least in the spiny mouse 182 
where this has been examined in some detail, with female fetuses showing higher levels of 183 
placental glycogen, peaking around mid-gestation [33]. In a poorly functioning placenta such 184 
as in IUGR pregnancies, placental glycogen accumulation may reflect storage for its own use, 185 
or inability to liberate glucose from the glycogen stores when needed. This would in theory 186 
result in reduced transport of glucose to the fetus and thus could be causal in the development 187 
of fetal growth restriction. An alternative hypothesis, specifically in cases of a high maternal 188 
glucose environment (e.g. diabetes), is that the placenta mounts a compensatory response and 189 
stores glycogen to limit excess glucose reaching the baby. Understanding placental glycogen 190 
biology, and the circumstances under which it is stored and/or released, may provide insights 191 
into pregnancies resulting in inappropriate fetal growth. 192 
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 193 
Detection of glycogen in placental tissues 194 
There are various methods that have been used for detection of glycogen in human and rodent 195 
placental tissue. For histological examination of glycogen deposits in tissue sections, often a 196 
simple Haematoxylin and Eosin (H&E) stain is used (for examples see [34-38] in Table 1 and 197 
Fig. 1), although this doesn’t specifically stain glycogen. Periodic Acid Schiff (PAS) is the 198 
primary stain used as an indicator of glycogen in the placenta (for examples see [33, 39-43] 199 
in Table 1 and Fig. 1), although it is not strictly glycogen-specific as it also stains 200 
glycoproteins, glycolipids and mucins in addition to the polysaccharides of glycogen. 201 
Therefore, use of PAS in combination with amylase or diastase, both of which break down 202 
glycogen, can be used to compare against PAS staining alone to confirm glycogen deposits. 203 
Best Carmine’s stain, an ammoniated carminic acid, specifically stains glycogen and has been 204 
used to stain mouse placenta [44] (Fig. 1). These stains allow the specific cells and location 205 
of glycogen accumulation to be identified in the placenta, but their quality is affected by both 206 
the fixative and temperature of fixation [45] and they provide more of a descriptive rather 207 
than a quantitative measure of glycogen. Nevertheless, stereological assessment of placental 208 
morphology is seen as an important technique for comparing normal pregnancies and those 209 
complicated by conditions such as preeclampsia/IUGR and asthma [46]. 210 
Recently, a histochemical staining method has been developed that utilises biotinylated BSA-211 
II (the lectin from Bandeiraea simplicifolia-II) which shows binding affinity for intracellular 212 
amylase-sensitive glycogen [21]. This method strongly stains cytotrophoblast cells in 213 
chorionic and anchoring villi in the placenta in early pregnancy. Ongoing differentiation of 214 
these cells during pregnancy results in a gradual decrease in staining intensity, suggesting that 215 
this lectin could be a useful marker for these cells in perturbed pregnancies where this 216 
differentiation may be affected.  217 
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Alternatively, many studies quantify glycogen content by homogenizing the tissue, extracting 218 
the glycogen [47, 48] and then using biochemical assays to calculate glycogen content, often 219 
relative to total placental protein (as per [49]). Others have utilised assays of glycogen 220 
synthase or glycogen phosphorylase activity (as per [48]) as measures of glycogen 221 
metabolism. However, although quantitative, these assays do not indicate which placental cell 222 
types are involved in glycogen storage. 223 
These different methods for assessing glycogen can result in conflicting conclusions with 224 
respect to alterations to placental glycogen under pathological scenarios. Indeed, although 225 
there are many examples in which glycogen levels have been shown to be altered (Table 1), 226 
some studies have shown no link between placental glycogen and pregnancy complications 227 
(for example [50-53]). Different methodologies may be a factor, but these studies also 228 
typically have small sample sizes, especially those conducted using human tissues. 229 
Additionally, male and female placentas are rarely investigated separately, and few studies 230 
investigate glycogen rich EVTs within the basal plate; the cells most analogous to rodent 231 
GlyT cells. As a further complication in mouse models, genetic background has been shown 232 
to impact on glycogen storage in the placenta, at least in the C57/Bl6 (Bl6) and 129S2/SvHsd 233 
(129) strains that have been closely investigated [54]. The Bl6 strain was shown to 234 
accumulate 2-fold higher glycogen in late gestation compared to the 129 strain, potentially 235 
protecting embryos from IUGR in situations where defects in the jz may affect glycogen 236 
storage [54]. Collectively, these methodological factors can produce variability in 237 
comparisons between disease states and normal pregnancies. 238 
 239 
Preclinical evidence of altered placental glycogen in rodent models of perturbed 240 
pregnancies 241 
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In animal studies, there are a large number and range of maternal conditions and/or 242 
environmental exposures that alter placental GlyT and glycogen stores. For example, 243 
exposure to the cancer drug cisplatin decreases GlyT numbers and alters the migration of 244 
these cells [55]. Moreover, a wide range of programming and disease models result in 245 
alterations in glycogen deposition within the junctional zone (Table 1). These alterations 246 
occur for various insults across different species and pregnancy time-points, all of which 247 
result in altered fetal growth, developmental abnormalities and/or disease outcomes in 248 
offspring. Alterations in placental GlyT are more profound in some models but occur in all 249 
the models to some degree. Interestingly, changes in placental GlyT are often sex-specific 250 
(Table 1), reflecting the sex-specific fetal outcomes that are often seen in perturbation 251 
models. Given the variety of preclinical models of pregnancy insults that demonstrate 252 
changes in placental glycogen, this suggests a potentially causal mechanistic pathway rather 253 
than an epiphenomenon. Table 1 is not designed to be an exhaustive list of all studies in 254 
which glycogen has been recorded, but rather to show the breadth of pregnancy perturbation 255 
models in which alterations in GlyT and/or glycogen stores have been reported. 256 
Mouse knockout studies have shed some light on the genes responsible for GlyT 257 
differentiation [56, 57]. The imprinted gene Phlda2 appears particularly central to GlyT 258 
development, as an up-regulation of Phlda2 expression results in a significant decrease in 259 
GlyT numbers and placental glycogen content, while decreased Phlda2 expression results in 260 
increased GlyT numbers and glycogen content [49, 58]. Remarkably, either loss or excess of 261 
GlyT and placental glycogen were associated with fetal growth restriction. While this is 262 
strong evidence that dysregulated placental glycogen handling results in inappropriate fetal 263 
growth, some caution is required in interpreting these observations; most gene knockouts 264 
affect multiple trophoblast lineages, making it difficult to directly link fetal growth 265 
abnormalities with aberrant GlyT biology specifically. Furthermore, GlyT cells may have 266 
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additional functions during pregnancy. GlyT invade the decidua and congregate near spiral 267 
arteries, possibly playing a role in their remodelling by breaking down the smooth muscle 268 
wall or extracellular matrix (ECM) to aid in endovascular trophoblast invasion [59]. GlyT 269 
secrete prolactin-like hormones (PRL7B1 and PRL2A1 for example) [60] and retinoic acid 270 
[44], and thus likely have an endocrine role also. In fact, GlyT become the main source of 271 
IGF2 during the last half of gestation [61], and placental-specific loss of IGF2 results in fetal 272 
growth restriction [62]. Future studies that manipulate genes specifically in the GlyT 273 
population are needed to clarify the relationship between placental glycogen handling and 274 
fetal growth.  275 
Furthermore, in all animal exposure models and most gene knockout models studied to-date, 276 
altered GlyT morphology and/or numbers have only been investigated in late gestation, 277 
making it difficult to interpret the nature or origin of this dysfunction. For example, an 278 
increase in the area occupied by placental GlyT at term may result from an earlier increase in 279 
GlyT proliferation, beyond the 250-fold increase normally seen throughout gestation [31]. 280 
Alternatively, GlyT invasion into the decidua may be impaired, leaving behind more GlyT 281 
within the jz than is normally observed at term, or GlyT may have failed to lyse at the end of 282 
gestation. Moreover, increased area occupied by GlyT may represent larger GlyT cells rather 283 
than more, as is seen in female placentas at term in the Spiny Mouse glucocorticoid exposure 284 
model (Table 1, [33]). This would implicate metabolic dysfunction rather than impacts on 285 
their developmental origins. Understanding the origin of the defect is critical to 286 
understanding how altered GlyT cells may contribute to placental dysfunction and perturbed 287 
fetal growth. 288 
 289 
Clinical evidence of altered placental glycogen in complicated pregnancies 290 
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In human pregnancies, two pathologies have primarily been associated with altered glycogen 291 
metabolism and/or deposition: PE, often resulting in IUGR, and diabetes. 292 
More than 20 years ago, it was observed in placentas from pregnancies complicated by PE 293 
that there was an increase in trophoblast glycogen content and glycogen synthase kinase 294 
(GSK) activity compared to placentas from normotensive, gestational age-matched 295 
pregnancies [63]. These differences were most pronounced in microvesicles isolated from 296 
their syncytiotrophoblasts [63]. The authors suggested glycogen accumulation may be a 297 
metabolic marker of immaturity of this cell which is unable to divide. This field received 298 
little subsequent investigation but data emerged almost a decade later to further implicate 299 
placental glycogen synthesis and deposition in PE [3]. This included evidence for increased 300 
expression of glycogen phosphorylase [64, 65], as well as increased activity of glycogen 301 
phosphorylase and glycogen synthase [63]. Increased glycogen deposits were also identified 302 
in cytotrophoblasts of terminal chorionic villi by ultrastructural imaging [66]. However, not 303 
all studies have reported differences in placental glycogen content in PE [52, 53]. As 304 
mentioned above, there may be various reasons for this. Nevertheless, other studies suggest 305 
that glycogen storage and/or turnover may be altered in PE. 306 
Interestingly, whilst diabetes, mostly type 1 diabetes or gestational diabetes mellitus (GDM), 307 
reduces maternal glycogen stores in peripheral tissues, the human placenta has increased 308 
glycogen stores in diabetic compared to non-diabetic pregnancies [19]. This has been 309 
observed as small deposits of glycogen in the interstitium of terminal villi at term [67], 310 
subsyncytially and in the basement membrane [39, 68]. Another histochemical study of the 311 
human placenta identified that the majority of the glycogen was deposited in cells 312 
surrounding the fetoplacental vasculature with little in the cytotrophoblast cells [69]. This 313 
suggests that the glucose contributing to the glycogen accumulation derives from the fetal 314 
rather than the maternal circulation and the placenta serves as a buffer for this excess fetal 315 
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glucose. Thus, fetal macrosamia should only occur in cases when fetal hyperglycaemia 316 
exceeds the placenta’s capacity to store excess fetal glucose [69]. 317 
There are some tantalizing indications that the mode of treatment of gestational diabetes 318 
affects overall placental glycogen content. Women treated with insulin have similar glycogen 319 
content to healthy women, whereas women undergoing a diet-intervention have only slightly 320 
reduced placental glycogen levels which may be related to the expression of insulin receptors 321 
in trophoblasts [70]. Primary trophoblast cells from healthy term deliveries cultured in 10 322 
mM glucose display intracellular glycogen ‘lakes’ independent of lipid concentrations [71], 323 
which suggests that hyperglycaemia rapidly increases glycogen deposition in the placenta. 324 
Glycogen deposition in the human placenta has not been studied in detail in most other 325 
complications of pregnancy. For example, a study examining placental morphometry in 326 
patients with asthma during pregnancy did not investigate glycogen deposition [72]. Several 327 
studies that included placentas from IUGR offspring reported no difference in glycogen 328 
deposition with PAS staining [39], or with electron microscopy [73]. The protein and 329 
phosphorylation levels of GSK were also not different in pregnancies affected by IUGR, 330 
despite decreased expression of upstream signalling proteins including IGF-1 receptor and 331 
AKT [74]. However, not all enzymes involved in glycogen synthesis have been studied in 332 
human placentas resulting in IUGR. 333 
 334 
Conclusions and future areas for research 335 
Collectively, there is accumulating data to suggest changes in placental glycogen deposition 336 
are a hallmark feature of a compromised pregnancy associated with fetal growth restriction 337 
and also, paradoxically, with fetal overgrowth. Future studies should use a combination of 338 
robust stereological and biochemical techniques to more thoroughly assess glycogen 339 
deposition and metabolism in the human placenta in a range of pregnancy complications. 340 
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Additionally, researchers using preclinical models of fetal growth restriction should examine 341 
placental glycogen and should importantly, determine if differences are sex-specific. Studies 342 
in preclinical rodent models also allow investigation of the placenta across gestation enabling 343 
the potential temporal changes of placental glycogen to be elucidated.  344 
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Table 1: Preclinical models demonstrating altered placental glycogen trophoblast cells (GlyT) in perturbed pregnancies. 
Maternal Insult Species Exposure/Treatment Findings Reference 
Alcohol Rat^ 
Periconceptional (E-4 to E4); 12.4% 
v/v EtOH 
↑ GlyT cell area in female term placentas (Fig. 1); 
IUGR 
[34] 
Hypoxia Rat 
Early to mid-gestation (E6.5 to E13.5); 
11% O2 
↑ endovascular GlyT invasion when hypoxia exposure 
between E6.5-E10.5; ↑ JZ/LZ ratio at E13.5 [75] 
Hypomagnesemia  Mouse^ 
4 weeks prior and throughout gestation; 
0.02% and 0.005% w/w Mg2+ 
↑ GlyT cell area in male and female placentas; IUGR 
and ↑ postnatal loss [35] 
Hypothyroidism Rat 
Throughout gestation; partial 
thyroidectomy 
↑ glycogen content by glucoamylase digest at E19 and 
at term in junctional zone; IUGR [32] 
IVF Mouse 
Prior to gestation; comparison of 
control, IVC and IVF 
↑ GlyT cell area in IVC and IVF; no change in Pcdh12 
(GlyT marker); ↑ Gys2 (glycogen metabolism) and ↑ 
Tpbpa (JZ marker); IUGR 
[42] 
Diabetes Rat 
Throughout gestation; STZ treatment 
prior to mating (35-60mg/kg) 
↑ GlyT numbers at term by histology; ↑ glycogen 
content by protein assay from E16; ↑ glycogen 
synthase/ phophorylase activity 
[19, 40, 41, 
48] 
Hyperglycaemia Rat 
Late gestation (E18 to E20); 40% 
glucose infusion 
↑ glycogen content by protein assay at E20.5 [76] 
Glucocorticoids 
Spiny 
mouse^ 
Mid-gestation (E20.5 to E23); 
125µg/kg DEX 
↑ GlyT cell area at E37 (term is E39) due to GlyT 
hyperplasia in males and GlyT hypertrophy in females 
[33] 
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Table 1: Continued. 
Maternal Insult Species Exposure/Treatment Findings Reference 
Placental underperfusion  Rat 
Late gestation (E16-E22); low sodium 
diet (0.03%) to reduce plasma volume 
expansion 
↑ GlyT cells in JZ at E22; IUGR [38] 
Placental underperfusion Rat 
Late gestation (E17); uterine ischemia/ 
reperfusion injury for 30 mins ↓ GlyT cell area (by 50%) at E18 in JZ; IUGR [36] 
Placental underperfusion Rat 
Mid-late gestation (E10-E20); ligation 
of abdominal aorta E10 
↓ GlyT cells at E15 and E20 [77] 
Protein restriction Rat 
Throughout gestation; low protein diet 
(6% casein) ↓ GlyT at E17 and E19; ↓ JZ/LZ at E17; IUGR [37] 
Protein restriction Mouse 
2 weeks prior and throughout gestation; 
low protein diet (6% casein) 
↓ GlyT cells at E10.5 and E17.5 by Pcdh12 mRNA; ↓ 
JZ from E10.5 by Tpbpa ISH (~20-30%); IUGR [78] 
Hypertension Rat 
Throughout gestation; stroke prone 
spontaneously hypertensive rat 
(SHRSP strain) 
↓ GlyT cells at E18 [43] 
E = embryonic day. IUGR = intrauterine growth restriction. STZ = streptozotocin. DEX = dexamethasone. JZ = junctional zone. LZ = labyrinth 
zone. IVF = in vitro fertilisation. IVC = in vitro culture. ^ = placental sex determined. ISH = in situ hybridisation. mRNA = messenger RNA. 
Pcdh12 = protocadherin 12; Tpbpa =  trophoblast-specific protein alpha; Gly2 = glycogen synthase 2. 
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Figure Legend 
Fig. 1. Glycogen trophoblast (GlyT) cell localization in the rodent placenta. A and B: 
Haematoxylin and eosin (H&E) staining of embryonic day 20 placentas from 
untreated/control (A) and periconceptional ethanol (B) exposed rat pregnancies. Main images 
at 1X magnification (scale bars 1000 µm) and inset images at 20X magnification (scale bars 
100 µm). Glycogen stores appear white in section. Images adapted from [34]. C and D: 
Embryonic day 14.5 mouse placenta stained with Periodic Acid Schiff (PAS) (C) and the 
glycogen-specific Best’s Carmine stain (D). The dark staining in the junctional zone 
corresponds with glycogen trophoblast cells. Note that PAS staining is more broad than 
Best’s Carmine, likely due to the wider range of substrates detected by PAS such as other 
glycoproteins, glycolipids and mucins. Scale bars as per A and B. 
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